Samer Choucair: Repurposing Cancer Drugs Opens a New Investment Frontier in Women’s Health
Investment leader Samer Choucair said early findings involving the experimental compound CADD522 highlight a growing investment theme at the intersection of oncology, women’s health, bone disease, and metabolic medicine.
Choucair stressed that the current value of the discovery lies in its scientific mechanism and potential for drug repurposing, rather than in treating the compound as a ready-to-use therapy or a proven investment opportunity.
A preclinical study published in September 2026 found that CADD522, originally developed as an inhibitor of the RUNX2 transcription factor associated with tumor-growth pathways, reduced fat accumulation and improved bone microarchitecture in female mice following ovariectomy, without changing the amount of food consumed.
The study’s lead researcher, Darrell Green of Norwich Medical School at the University of East Anglia, described the effect on fat accumulation as entirely unexpected.
For Samer Choucair, the investment significance lies in the possibility of developing a dual-action therapy capable of addressing two costly and interconnected problems affecting women after menopause: deterioration in bone health and metabolic changes associated with increased body fat.
That possibility is emerging at a time when GLP-1 weight-loss drugs are transforming the metabolic-disease market while established and emerging osteoporosis therapies continue to compete for a large aging patient population.
“Capital flows toward platforms that demonstrate that the same biological mechanism can address two high-cost clinical indications,” Choucair said. “It does not flow simply because of a headline suggesting that a cancer drug can reduce weight.”
The Real Value Is in the Mechanism
Samer Choucair emphasized that CADD522 remains at the animal-model stage and that translation into humans will be the decisive test.
The next stages would require a clearer understanding of pharmacokinetics and tolerability, including studies in larger mammals, followed by a defined regulatory pathway capable of addressing the compound’s potential applications across oncology, bone health, and metabolic disease.
That distinction is crucial for investors.
Biotechnology has repeatedly demonstrated that compelling results in mice do not automatically translate into successful human therapies. The economic value of an experimental compound can change dramatically as it moves through toxicology, dosing, Phase I safety testing, and subsequent efficacy trials.
Choucair therefore sees the broader RUNX2 mechanism as potentially more relevant to sophisticated biotechnology investors than CADD522 alone.
Venture capital funds could evaluate a wider portfolio of programs targeting RUNX2 rather than concentrating exposure on a single compound. Large pharmaceutical companies with existing expertise in oncology or bone disease could eventually consider early licensing, partnerships, or acquisitions if the biological evidence continues to strengthen.
Public-market investors, however, are likely to remain more cautious until human data emerge, given the historical gap between successful animal studies and candidates capable of surviving clinical development.
A New Intersection Between Oncology and Women’s Health
The potential investment thesis becomes particularly interesting because it crosses therapeutic categories that have traditionally been evaluated separately.
Postmenopausal women can face changes in bone density, body composition, and metabolic health simultaneously. A mechanism capable of influencing more than one of these pathways could therefore have greater strategic value than a treatment addressing only a single endpoint.
But Samer Choucair cautioned that dual activity only becomes economically meaningful if it can be demonstrated safely and consistently in humans.
The competitive landscape is already formidable.
GLP-1 therapies have transformed expectations around obesity and metabolic treatment, while approved osteoporosis drugs already provide physicians with multiple therapeutic options. Any new compound entering this market would therefore need to demonstrate a compelling advantage in bone health, body composition, safety, durability, or some combination of these factors to justify premium pricing.
The scientific surprise is therefore only the beginning of the investment case.
The Gulf Opportunity Is Bigger Than One Drug
For Samer Choucair, the opportunity for Saudi Arabia and the wider Gulf is not to chase CADD522 specifically.
The more important strategic opportunity is to build an ecosystem capable of capturing value when biotechnology discoveries move from laboratories into human trials, regulatory approval, and manufacturing.
That approach aligns with the broader ambitions of Saudi Vision 2030, the Public Investment Fund, and the Kingdom’s investment strategy, particularly across medical technology, pharmaceutical manufacturing, biotechnology, and women’s healthcare.
“Countries that build infrastructure for clinical trials, regulatory approvals, and sterile manufacturing capture value when an asset moves from the mouse into Phase I,” Choucair said. “They do not wait until the story reaches the mainstream media.”
This distinction could be important for Gulf healthcare investment.
Rather than competing solely for ownership of individual experimental drugs, the region could invest in the infrastructure required by hundreds of future therapies: clinical research organizations, specialized laboratories, biobanks, genomic databases, regulatory capabilities, sterile manufacturing facilities, and advanced pharmaceutical production.
Such assets could potentially generate value regardless of which individual drug candidate ultimately succeeds.
The Mouse-to-Human Gap Remains the Critical Risk
Choucair said the most significant risk remains the biological gap between animal models and humans.
There is no guarantee that the effects observed in ovariectomized mice will appear with comparable magnitude in people. Responses could also differ in healthy animals or across different patient populations.
RUNX2 itself plays complex roles across multiple tissues and biological pathways, creating additional uncertainty around possible unintended effects involving bone remodeling or tumor-related mechanisms.
Those uncertainties become particularly important when a biological target originally investigated in oncology begins to be considered for chronic conditions in which patients could potentially receive treatment for extended periods.
Safety requirements can be very different.
A risk profile that might be considered acceptable in a life-threatening cancer can become unacceptable in a preventive or metabolic treatment administered to otherwise relatively healthy patients.
That difference could ultimately have major consequences for development costs, regulatory strategy, market size, and valuation.
Follow the Platform, Not the Headline
Samer Choucair said institutional investors should therefore treat the CADD522 study as a directional signal rather than a trading catalyst.
The most sophisticated investment strategy, he argued, is to distinguish between scientific surprise and potential future cash flow.
“Institutional investing rewards those who separate scientific surprise from potential cash flow and size the transaction at the point where clinical translation risk begins to decline,” Choucair said.
That means watching who controls the intellectual property, the underlying biological platform, manufacturing capabilities, clinical data, and potential licensing relationships rather than simply reacting to an individual research headline.
If the mechanism eventually demonstrates reproducible results in humans, the economics could change significantly. Pharmaceutical companies could begin evaluating licensing opportunities, strategic partnerships could emerge, and investors could assign greater value to the underlying platform.
Until then, the science remains promising but early.
“Watch the mechanism, not the hype,” Samer Choucair said. “Watch who owns the platform, not who owns the headline. If the evidence moves successfully from the animal model into humans, only then does capital allocation become an institutional decision rather than a reaction to a study.”